Medical Supplies Market – Global Market Insights, Size and Growth, 2023

Medical Supplies Market

Medical supplies are the medical instrument and device supplies, that are used in various medical centers, medical institutions and hospitals. Various medical instruments and devices include thermometers, glucose meters, blood processing devices, wound care instruments and accessories, and monitoring systems. The demand for the medical supplies is experiencing an increasing trend since the market players are introducing technically advanced medical supplies that can aid medical professionals to handle their patients in a better way. The outpatient facilities and hospitals are adopting strict policies towards infection- prevention for better care of the patient, which is driving the growth of the market.

Explore Report at: https://www.psmarketresearch.com/market-analysis/medical-supplies-market

Based on application, the global medical supplies market is segmented into urology, ophthalmology, radiology, anesthesia, sterilization, cardiology, wound care and others. Anesthesia was the largest application in 2016 due to increase in the number of surgical procedures performed and rise in respiratory diseases.

Based on type, the global medical supplies market is categorized into sterilization consumables, personal protective equipments (PPE), infusion products, radiology consumables, wound care consumables, diagnostic supplies, inhalation products, dialysis consumables, infection control supplies, intubation and ventilation supplies, hypodermic products, and other supplies. Among different types of medical supplies, dialysis consumable segment is expected to witness the fastest growth during the forecast period (2017-2023) due to increase in renal disease cases, rise in diabetic patients and aging population.

Global medical supplies market is expected to grow during the forecast period due to the growing population, increase in number of hospitals, rise in the frequency of communicable diseases, and aging population. Also, increase in medical conditions such as diabetes and renal disease, rise in surgeries, rise in hospital acquired infections and increase in awareness are driving the growth of the global medical supplies market. The increase in number of hospital acquired infection cases have significant positive impact on the growth of the global medical supplies market. According to the World Health Organization (WHO), every 10 people in developing countries and 7 in developed countries acquire at least one infection from hospital, of every 100-hospitalized patient, at any given point of time.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/medical-supplies-market/report-sample

Global medical supplies market is highly competitive and major players are acquiring smaller players to increase their market share. The key players in the global market are Boston Scientific, Medtronic plc, Baxter International Inc., Johnson & Johnson. Other players in this market are Cardinal Health Inc., Halyard Health Inc., Thermo Fisher Scientific, B. Braun, Becton, Dickinson and Company, and 3M Company.

Advertisements

Image Guided Surgery Devices Industry Outlook, Growth Prospects and Key Opportunities

Image Guided Surgery Devices Market AnalysisThe global image guided surgery devices market is likely to grow significantly during the forecast period, due to increasing prevalence of chronic diseases, and cancer, rising geriatric population and increasing cases of neurological disorders. In addition to these factors, rising healthcare expenditure and technological advancements in medical imaging also contributes to the growth of the overall market. High cost of imaging techniques and stringent regulatory requirements are some of the key factors restraining the global market growth.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/image-guided-surgery-devices-market/report-sample

As per the findings of the research, the CT is the largest segment, based on device type, in the global image guided surgery devices market. CT is a non-invasive, accurate and fast diagnostic imaging test. It uses x-ray equipment to produce 3D images by taking series of images from different angles. Each image created during the CT procedure shows the bones, tissues and organs in a thin “slice” of the body.

It provides cross-sectional images generated during the CT scan and can be reformatted in multiple planes. It is used for diagnosing skeletal abnormalities, blood clots, blood vessel aneurysm and cancer. Neurology has been the largest application area for image guided surgery devices, followed by orthopedic surgery, ENT surgery, oncology surgery and others.

Browse Report Description at: https://www.psmarketresearch.com/market-analysis/image-guided-surgery-devices-market

Some of the key players in the global image guided surgery devices market include Siemens AG, GE Healthcare, Koninklijke Philips N.V., Canon Inc., Hitachi, Ltd., KARL STORZ GmbH & Co. KG., Medtronic, Inc., St. Jude Medical, Inc., Varian Medical Systems, Inc., Smith & Nephew plc, Integra LifeSciences Corporation and Zimmer Holdings, Inc.

 

Smart Pulse Oximeters Market – Global Industry Size, Share and Growth, 2023

Smart Pulse Oximeters MarketSmart pulse oximeters are non-invasive medical devices that are used to measure various health parameters such as pulse rate, heart rate and oxygen saturation level. These devices help in the early detection of various diseases such as sleep problems, respiratory diseases, and cardiac diseases. However, smart pulse oximeters readings may get affected by low blood pressure, cold fingers, nail polish, and artificial nails. The smart pulse oximeters market is expected to have a considerable growth during the forecast period. According to the World Health Organization (WHO), around 3 million people died of chronic obstructive pulmonary disease (COPD), in 2015. It further reported that COPD is likely to increase in coming years due to higher smoking prevalence and aging populations in many countries. Therefore, the increasing prevalence of the respiratory diseases is expected to drive the growth of the global smart pulse oximeters market.

Explore Report at: https://www.psmarketresearch.com/market-analysis/smart-pulse-oximeters-market

Based on product type, the smart pulse oximeter market is segmented into fingertip pulse oximeters, hand-held pulse oximeters, wrist-worn pulse oximeters, and pediatric pulse oximeters. Fingertip pulse oximeters held the largest share of the smart pulse oximeters market, in 2016, and is expected to maintain its position during the forecast period, mainly due to its light weight, ease of use, and rising prevalence of respiratory diseases. Moreover, WHO safety pulse oximetry project for the improvement in the health of the people in middle-income countries is also expected to further boost the growth of the smart pulse oximeters market.

Smart pulse oximeters market is expected to grow significantly during the forecast period. Some of the major factors driving growth of the global market are growing geriatric population, technological advancements, rise in prevalence of respiratory diseases, and growing demand for portable monitoring devices.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/smart-pulse-oximeters-market/report-sample

According to the United Nations Department of Economic and Social Affairs (UNDESA) report the number of people aged 60 years or over is projected to grow by 56%, globally, i.e. from 901 million in 2015 to 1.4 billion by 2030. Also, the global aging population is projected to reach nearly 2.1 billion, by 2050. Thus, with the rise in aging population, the use of smart pulse oximeters has been increasing for early detection of diseases.

Some of the key players in the global Smart pulse oximeters market are Contec Medical Systems Co., Ltd., General Electric Company, Halma PLC, Koninklijke Philips N.V., Masimo Corporation, Medtronic PLC, Nonin Medical, Inc., Omron Corporation, Smiths Group PLC, and Technocare Medisystems.

Surgical Simulation Market – Global Industry Analysis, Size, Growth, 2023

Surgical Simulation MarketSurgical simulation is a technology that is developed in order to stimulate surgical procedures for the purpose of training healthcare professionals, without using any subject such as a human body or animal. The key concept of surgical simulator is based on the video games that were developed in 1980’s, and now it offers advancements such as three-dimensional graphics, motion sensors for realistic movements in order to simulate the real situation. The trainings conducted to teach how to perform surgeries, using these simulators is known as surgical simulation. The global surgical simulation market is growing due an increase in the number of diseases, which has further led to a rise in the requirement of doctors. Doctors need to be trained about surgeries without actually involving a subject. The most common type of surgery that is being explained through this method is laparoscopic surgery, although it has also been used to do a trial run before other kinds of procedures. With public pressure for increased oversight of surgeons in training, prevention of medical errors, reduction in healthcare costs and decreased working hours, current doctors have a very different training experience these days, as compared to the past. Limited working hours have led to a reduced exposure of surgical trainees towards operative procedures and the ability to practice those associated technical skills. Bridging this educational gap has become important, since proficiency based evaluation overtakes the traditional time-based model.  Many now look to simulation as the possible solution for deficits emerging in current surgical training and as a way to improve patient safety and possibly overall costs. Surgical simulation is best suited for two types of skills, namely eye-hand coordination and the ability to perform three dimensional actions.

Explore Report at: http://bit.ly/2hX6E9D

The surgical simulation market is divided on the basis of application and end user. On the basis of application, surgical simulation is applied to various surgeries such as laparoscopic, gynecological, cardiovascular, arthroscopic physiotherapy, occupational therapy and others. The cardiovascular surgery accounts for holds the largest share of the market.

Technological innovations in simulators, rising demand for minimally invasive treatments, increasing focus on the safety of patient and increasing healthcare spending are some of the drivers supporting the growth of global surgical simulation market.

Request for Report Sample at: http://bit.ly/2i1dlrq

According to the Centers for Disease Control and Prevention (CDC), total national health expenditure in the U.S. was $3.0 trillion in 2014, and per capita national health expenditure was $9,523. According to the U.K. Office for National Statistics (ONS), the U.K.’s total healthcare expenditure was $297.8 billion in 2014.

Major key players in the global surgical simulation market include Laerdal Medical, 3D Systems Inc., Gaumard Scientific, Limbs & Things Ltd., Kyoto Kagaku Co. Ltd, Mentice AB, Simulab Corporation, Surgical Science Sweden AB, Simulaids Inc.

HIV Diagnosis Market Trends, Size, Growth and Future Scope

HIV Diagnosis Market

The global HIV diagnosis market is likely to grow significantly during the forecast period, due to rising prevalence of HIV/AIDS, growing awareness leading to high number of blood donations and blood transfusions, and advantageous features of point of care instruments and kits. In addition, rising healthcare expenditure on HIV and related activities further contributes to the growth of the overall market. High cost of automated HIV diagnosis procedures and lack of skilled professionals are some of the key factors restraining the growth of global HIV diagnosis market.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/hiv-diagnosis-market/report-sample

As per the findings of the research, based on products, consumables segment is the largest product category in the global HIV diagnosis market. Antibody test has been the largely performed test of the global HIV diagnosis market, followed by viral load, CD4, early infant diagnosis and viral identification. Diagnostic laboratories have been the largest end user of HIV diagnosis, followed by hospitals, research institutes and others.

The healthcare expenditure for the purpose of alleviating the potential epidemic situation of HIV, has increased over the past few years in many low and middle income as well as developing countries. According to the data published by UNAIDS, $19.0 billion was spent on the HIV and AIDS related activities in low- and middle-income countries in 2015, of which 57% came from domestic budgets of the governments of these countries. Considering the increasing incidence of HIV, the UNAIDS estimated that approximately $26.2 billion will be required to respond to the epidemic of HIV infection expected in 2020 and around $23.9 billion will be required for the same, in 2030. The variation in healthcare spending across regions is thought to be related to the relative burden of the disease in that region, which in case of Sub-Saharan Africa is significantly high. The overall healthcare spending on HIV and related activities has increased over the years, which in turn is expected to drive the growth of the global HIV diagnosis market.

Browse Report Description at: https://www.psmarketresearch.com/market-analysis/hiv-diagnosis-market

Some of the key players in the global HIV diagnosis market include Siemens AG, F. Hoffman La Roche Ltd., Danaher Corporation, Abbott Laboratories, Ltd., Thermo-Fisher Scientific Inc., Merck KGaA, Becton, Dickinson & Company, Alere Inc., Bio-Rad Laboratories and Hologic Inc.

New Growth Opportunities lie in the Asia-Pacific Active Implantable Medical Devices Market, 2023

Active-Implantable-Medical-Devices-MarketThe global active implantable medical devices market is likely to grow from $17.0 billion in 2016 to $28.9 billion by 2023. Technological advancements, increasing prevalence of cardiovascular diseases, rising healthcare expenditures and increasing research and development activities have been driving the growth of the global active implantable medical devices market. The market is further expected to gain revenue due to increasing geriatric population and incidence of neurological disorders. Development of subcutaneous implantable cardioverter defibrillators along with the increasing demand from developing nations is expected to create ample growth opportunities in the global active implantable medical devices market.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/active-implantable-medical-devices-market/report-sample

As per the findings of research, implantable cardioverter defibrillators held the largest share in the global active implantable medical devices market in 2016, primarily due to the development of technologically advanced devices and increasing prevalence of cardiovascular diseases. The neurostimulators market is expected to witness the highest growth during the forecast period. This growth of neurostimulators is attributed to the increasing incidence of neurological disorders and increasing demand from emerging economies. Among different type of implantable cardioverter defibrillators, transevenous implantable cardioverter defibrillators held larger share in the global active implantable medical devices market in 2016, and it is also expected to witness higher growth during the forecast period. Increasing research and development activities and rising compliance for technological innovations and data driven customizations are driving the growth of the global transvenous implantable cardioverter market.

Explore Report at: https://www.psmarketresearch.com/market-analysis/active-implantable-medical-devices-market

Active Implantable Medical Devices Market

Key companies in the active implantable medical devices market are acquiring other companies to strengthen their position in the global market. In January 2017, Abbott completed the acquisition of St. Jude Medical, Inc., including its atrial fibrillation, structural heart and heart failure business as well as neuromodulation business. Similarly, in January 2015, Medtronic plc completed the acquisition of Covidien plc. Under the terms of the acquisition agreement, Medtronic, Inc. and Covidien plc are now combined under Medtronic plc. The acquisition strengthened position of the company in the global market with a large number of product offerings.

Some of the other key players in the market include Boston Scientific Corporation, BIOTRONIK SE & Co. KG, LivaNova PLC, William Demant Holding A/S, Nurotron Biotechnology Co. Ltd., Sonova Holding AG, and MED-EL.

Life Science Instrumentation Market – Global Industry Analysis, Size, Growth and Opportunities

ESA / ESTEC Laboratoria

The global life science instrumentation market is growing due to the technological advancements, increase in funding for life science research, and increasing food safety concerns. Moreover, the increasing research and development activities in pharmaceuticals and biotechnology industries are supporting the growth of the global market. Among the various technologies, next-generation sequencing segment would witness the fastest growth during the forecast period. Development of advanced sequencing platforms, increasing application areas of next-generation sequencing would have high positive impact on the growth of the life science instrumentation market for next generation sequencing. Pharmaceuticals and biotechnology companies were the largest end user of life science instrumentation market in 2015.

Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/life-science-instrumentation-market/report-sample

The increasing demand for analytical instruments, growing research proteomics research activities, and high growth in emerging economies offer ample growth opportunities in life science instrumentation market. Major analytical instrument manufacturers are focusing for the development of miniaturized instruments, which is the key trend witnessed in the global market. Increasing compliance for hyphenated technologies and increasing collaborations between analytical instrument manufacturers and academic and research institutes are other trends witnessed in the global life science instrumentation market. However, dearth of skilled professionals and high cost of analytical instruments would hinder the growth of the global market to some extent.

Explore more or request TOC on Life Science Instrumentation Market” at: https://www.psmarketresearch.com/market-analysis/life-science-instrumentation-market

The key players operating in the global life science instrumentation market are Danaher Corporation, Agilent Technologies, Inc., Shimadzu Corporation, Thermo Fisher Scientific Inc., PerkinElmer Inc., Becton, Dickinson and Company, Bruker Corporation, Bio-Rad Laboratories, Inc. and Waters Corporation.

Graft Versus Host Disease Treatment Market – Global Industry Analysis, Growth, 2023

Graft Versus Host Disease Treatment Market

The global graft versus host disease (GVHD) treatment market is expected to witness considerable growth due to increasing number of hematopoietic stem cell transplantations (HSCTs), advancement in technologies, and increasing collaboration among the pharmaceutical companies. The regulatory bodies are supporting the graft versus host disease market by providing designations and grants for speeding up the drug development process. Currently, there are more than 15 targets, which are being used for the treatment of GVHD including T lymphocytes, OX40, Bruton’s tyrosine kinase, Toll-like receptors, tumor necrosis factor alpha, neutrophil elastase, and several B and T lymphocytes. Some of the companies use their own technologies for the development of drugs for graft versus host disease such as Bellicum Pharmaceuticals, Inc. and Targazyme, Inc.  Bellicum Pharmaceuticals, Inc. is using CaspaCIDe technology and Targazyme, Inc. is using Fucosylation technology.

Explore Report at: https://www.psmarketresearch.com/market-analysis/gvhd-treatment-market

The pipeline of GVHD is very rich with more than 60 drugs. Top pharmaceutical companies such as Dr. Falk Pharma GmbH and Mallinckrodt plc are expected to launch their products in coming years, as the products are in Phase III stage of development. The therapeutics involved in the treatment of GVHD comprise different molecule types including antibody drug conjugate, antibodies, cell therapy, monoclonal antibodies and recombinant proteins.

GVHD is a common condition associated with allogeneic hematopoietic stem cell transplantation. It occurs when the donor cells are rejected and attack the recipient’s cells as foreign cell. It can progress from mild to severe forms as either acute GVHD (aGVHD) or chronic GVHD (cGVHD). The most common organs affected by aGVHD and cGVHD include skin, gastrointestinal tract, liver, oral mucosa and eyes. The affected people were recognized on the basis of number of allogeneic cell transplantation.

Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/gvhd-treatment-market/report-sample

Some of the key players operating in the global market are Dr. Falk Pharma GmbH, Mallinckrodt Pharmaceuticals, Apceth GmbH & Co. KG, Targazyme Inc., Bellicum Pharmaceuticals, Inc., Cellect Biotechnology Ltd., Sanofi, Novartis AG, Gilead Sciences, Inc., AbbVie Inc., and Takeda Pharmaceutical Company Ltd.

Natural Killer Cell Therapeutics Market – Pipeline Analysis, Size and Growth, 2023

The global natural killer (NK) cell therapeutics market is expected to witness considerable growth due to increasing awareness regarding immunotherapy, advancement in technologies, high demand for safe and effective medication, reduction of side effects, high prevalence of chronic diseases such as cancer and cardiovascular diseases, and increasing incidences of infectious diseases. The regulatory bodies are supporting the growth of the global market by providing funding, designations and grants for speeding up the drug development process. Some drug candidates, such as Mogamulizumab, Lorvotuzumab Mertansine, AFM 13, FPA144, and NKTT-120, got orphan drug designation and fast track designation for NK cell therapeutics.

Explore Report at: https://www.psmarketresearch.com/market-analysis/nk-cell-therapeutics-market

The pipeline of NK cell therapeutics market is rich with more than 30 drugs. The pharmaceutical companies are actively involved in the research and development of drug for NK cells. Kyowa Hakko Kirin Co., Ltd. has Mogamulizumab drug in its Phase III clinical trial for NK cells therapeutics. Increasing use of combination therapy of NK cells is also a potential growth driver for the growth of the global market. Use of NK cells with Chimeric Antigen Receptor (CAR) T-Cell therapy helps to enhance the efficacy of the medication.

NK cells are granular lymphocytes that provide innate immunity and first line of defense against viral infections and cancer. Natural killer cells are made up of 5–15% circulating lymphocytes. It is found in peripheral tissues including liver, peritoneal cavity, and placenta. NK cell are activated by interleukins that is capable of extravasations and infiltration into tissues.

Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/nk-cell-therapeutics-market/report-sample

Some of the key players operating in the global NK cells market are Chipscreen Biosciences, Ltd. Affimed N.V., Altor BioScience Corporation, Innate Pharma S.A., Takeda Pharmaceutical Company Limited, Sorrento Therapeutics Inc., NantKwest Inc., Bristol-Myers Squibb, and NKT Therapeutics, Inc.

ADCs Therapeutics Market – Pipeline Analysis, Share, Growth and Forecast to 2023

The global antibody drug conjugates therapeutics market is expected to witness significant growth due to current unmet medical need of some chronic diseases such as cancer and immunological diseases, increasing prevalence of such diseases, advancement in technologies and high demand for safe and effective medication. The regulatory bodies are supporting the ADCs market by providing designations and funding for speeding up the drug development process. In April 2015, ImmunoGen, Inc. drug candidate Mirvetuximab soravtansine got orphan drug designation by European Medicine Agency for the treatment of ovarian cancer.

Explore Report at: https://www.psmarketresearch.com/market-analysis/adcs-therapeutics-market

The pipeline of ADCs is rich with more than 200 drugs. The pharmaceutical companies are actively involved in the research and development of drug for ADCs. Trastuzumab emtansineis, a Phase III clinical trial drug candidate of Genentech, Inc., utilizes Tumor-Activated Prodrug technology for the treatment of HER2-positive primary breast cancer. The drug is already marketed under trade name Kadcyla for the treatment of advanced human epidermal growth factor receptor 2 (HER2)-positive gastric cancer and early HER2-positive breast cancer.

ADCs are prepared by linking biologically active cytotoxic drugs to monoclonal antibodies. An ADC comprises of a monoclonal antibody, cytotoxic drug and a linker. ADCs have specific targeting ability of monoclonal antibody, and hence these are capable of distinguishing healthy and diseased cells. Moreover, the cancer-killing ability of cytotoxic drugs makes ADCs more effective against the tumor cells. These characteristics increase the specificity and maximize the efficacy of ADCs. The antibody component of ADCs recognizes the target antigen and binds with it. After binding with the antigen, the cytotoxic component is released inside the tumor cell, causing its death or degeneration. The significant potential of ADCs in cancer treatment has attracted many researchers and healthcare providers to develop new antibody therapeutics using ADC technology.

Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/adcs-therapeutics-market/report-sample

Some of the key players operating in the global market are ImmunoGen, Inc., Takeda Pharmaceutical Company Limited, Seattle Genetics, Inc., F. Hoffmann-La Roche AG, BioAtla LLC, Philogen S.p.A., Viventia Biotechnologies, Inc., Sutro Biopharma, Inc., Sorrento Therapeutics, Inc., and Immunobiochem Corporation.